{"id":18670,"date":"2026-06-01T15:15:07","date_gmt":"2026-06-01T15:15:07","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?p=18670"},"modified":"2026-06-01T15:19:24","modified_gmt":"2026-06-01T15:19:24","slug":"lontario-devient-la-premiere-province-a-prendre-en-charge-lencorafenib-pour-le-cancer-colorectal-avec-mutation-du-gene-braf","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/lontario-devient-la-premiere-province-a-prendre-en-charge-lencorafenib-pour-le-cancer-colorectal-avec-mutation-du-gene-braf\/","title":{"rendered":"L&rsquo;Ontario devient la premi\u00e8re province \u00e0 prendre en charge l&rsquo;encorafenib pour le cancer colorectal avec mutation du g\u00e8ne BRAF"},"content":{"rendered":"<p><span data-contrast=\"auto\">L&rsquo;Ontario est devenue la premi\u00e8re province du Canada \u00e0 prendre en charge l&rsquo;encorafenib\u00a0(Braftovi) pour les patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique avec mutation BRAF V600E, dans le cadre du\u00a0programme visant \u00e0 acc\u00e9l\u00e9rer l&rsquo;acc\u00e8s aux traitements anticanc\u00e9reux prioritaires.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h4>Qu&rsquo;est-ce que le programme FAST ?<\/h4>\n<p><span data-contrast=\"auto\">Le programme\u00a0Ontarien \u00ab Funding\u00a0Accelerated\u00a0for\u00a0Specific\u00a0Treatments\u00a0\u00bb (FAST) acc\u00e9l\u00e8re le processus menant\u00a0\u00e0\u00a0l&rsquo;autorisation r\u00e9glementaire\u00a0de\u00a0la prise en charge publique des traitements anticanc\u00e9reux. L&rsquo;encorafenib\u00a0est le premier traitement de Pfizer \u00e0 b\u00e9n\u00e9ficier d&rsquo;un acc\u00e8s prioritaire dans le cadre de ce programme,\u00a0suite\u00a0\u00e0\u00a0une\u00a0recommandation positive de remboursement de l&rsquo;Agence canadienne des m\u00e9dicaments.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Au Canada, le d\u00e9lai moyen d&rsquo;attente avant que les m\u00e9dicaments oncologiques ne soient pris en charge par l&rsquo;assurance-maladie,\u00a0est d&rsquo;environ 18,9 mois, ce qui repr\u00e9sente un fardeau consid\u00e9rable pour les patients atteints d&rsquo;un cancer avanc\u00e9. Le programme FAST vise \u00e0 combler cet \u00e9cart.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h4>Qu&rsquo;est-ce que cela signifie pour les patients ?<\/h4>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"2\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Les patients\u00a0Ontariens atteints d&rsquo;un cancer colorectal m\u00e9tastatique avec mutation BRAF V600E,\u00a0peuvent d\u00e9sormais acc\u00e9der \u00e0 l&rsquo;encorafenib,\u00a0financ\u00e9 par l&rsquo;\u00c9tat sans attendre les d\u00e9lais de remboursement habituels.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"2\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">L&rsquo;encorafenib\u00a0doit \u00eatre utilis\u00e9 en association avec le\u00a0c\u00e9tuximab\u00a0(et une chimioth\u00e9rapie, selon l&rsquo;indication) et n\u00e9cessite la confirmation de la mutation BRAF V600E par des tests valid\u00e9s.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"2\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><span data-contrast=\"auto\">Les patients des autres provinces ne sont pas encore couverts \u2013 les d\u00e9fenseurs de cette cause appellent les autres provinces et territoires \u00e0\u00a0inaugurer\u00a0des programmes acc\u00e9l\u00e9r\u00e9s similaires.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"auto\">\u00ab En tant que survivant d\u2019un cancer colorectal, je sais que le diagnostic peut \u00eatre d\u00e9vastateur\u00a0et pour les patients pr\u00e9sentant une mutation BRAF V600E, le pronostic peut \u00eatre particuli\u00e8rement difficile. L\u2019acc\u00e8s acc\u00e9l\u00e9r\u00e9 en Ontario repr\u00e9sente une victoire pour la m\u00e9decine de pr\u00e9cision. \u00bb<\/span><\/i><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u2014 Barry Stein,\u00a0pr\u00e9sident, Cancer colorectal Canada<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p>***<\/p>\n<p><span class=\"TextRun SCXW123308716 BCX0\" lang=\"FR-CA\" xml:lang=\"FR-CA\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW123308716 BCX0\">26 mai 2026<\/span><\/span><span class=\"EOP Selected SCXW123308716 BCX0\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&rsquo;Ontario est devenue la premi\u00e8re province du Canada \u00e0 prendre en charge l&rsquo;encorafenib\u00a0(Braftovi) pour les patients atteints d&rsquo;un cancer colorectal m\u00e9tastatique avec mutation BRAF V600E, dans le cadre du\u00a0programme visant \u00e0 acc\u00e9l\u00e9rer l&rsquo;acc\u00e8s aux traitements anticanc\u00e9reux prioritaires.\u00a0 Qu&rsquo;est-ce que le programme FAST ? Le programme\u00a0Ontarien \u00ab Funding\u00a0Accelerated\u00a0for\u00a0Specific\u00a0Treatments\u00a0\u00bb (FAST) acc\u00e9l\u00e8re le <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/lontario-devient-la-premiere-province-a-prendre-en-charge-lencorafenib-pour-le-cancer-colorectal-avec-mutation-du-gene-braf\/\">&#8230;<\/a><\/p>\n","protected":false},"author":4,"featured_media":18669,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[42,98],"tags":[],"class_list":["post-18670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogue","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/18670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=18670"}],"version-history":[{"count":2,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/18670\/revisions"}],"predecessor-version":[{"id":18672,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/18670\/revisions\/18672"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/18669"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=18670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=18670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=18670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}